Nicholson Nur

CIK 00018273172 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001827317

Recent Transactions

50 trades

Award
Kailera Therapeutics, Inc.$KLRA
Stock Option (right to buy)
2026-09-07+220,000→ 220,000 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−28,367→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−35,472→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+22,610→ 22,610 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+45,220→ 45,220 total
Disposition from Tender
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−116,338→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−22,610→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−45,000→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−50,974→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−115,281→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (right to buy)
2026-05-14−82,500→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−45,220→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−27,320→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−9,754→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−5,645→ 0 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−41,250→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+41,250→ 41,250 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−24,284→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14+24,284→ 24,284 total
Disposition to Issuer
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-05-14−45,220→ 0 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-28+45,220→ 116,338 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-22$21.77/sh−7,725→ 71,118 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-20$19.79/sh−2,203→ 78,843 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-13$22.19/sh−2,618→ 81,046 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-06-09$19.39/sh+82,500→ 82,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-29$29.52/sh−825→ 83,664 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-22$30.43/sh−3,948→ 84,489 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-21+36,426→ 88,437 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-17$29.96/sh−2,145→ 52,011 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-13$28.70/sh−2,632→ 54,156 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-13$58.13/sh−3,452→ 56,287 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-13$57.31/sh−7,768→ 59,739 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-29$64.14/sh−835→ 67,507 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-22$65.00/sh−2,593→ 68,342 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-16$66.30/sh+28,367→ 28,367 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16$66.81/sh−1,857→ 70,935 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16+19,508→ 72,792 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-09-18−9,719→ 115,281 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-18$46.15/sh−10,631→ 53,284 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-18$42.21/sh−9,719→ 63,915 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-09-18$29.76/sh+9,719→ 73,634 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21+9,886→ 64,328 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21$58.50/sh−825→ 63,503 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-02-21+14,023→ 14,023 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-27$52.77/sh−551→ 54,442 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-20$52.05/sh−2,034→ 54,993 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-12$52.66/sh+35,472→ 35,472 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-12+22,580→ 57,027 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-04-25−11,250→ 0 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-04-25−1,875→ 33,680 total

Companies

Recent Filings

Address

C/O KAILERA THERAPEUTICS, INC. 180 THIRD AVENUE, 4TH FLOOR

WALTHAM, MA, 02451

View on SEC.gov